Expert Interviews

Sarah Raaii, co-chair of McDermott Will & Emery’s multidisciplinary post-Roe team, and Cat Duffy, policy analyst of the National Health Law Program, address the Dobbs v. Jackson Women's Health Organization decision of the U.S. Supreme Court in which the court held that the Constitution of the United States does not confer a right to abortion.

A hematologic expert explains the role gene therapy might play with Hemophilia B.

Dr Charles discusses the clinical impacts that nonmedical switching of biologic treatments can have on quality of patient care.

Scott Whittle, MD, uses his knowledge and experiences as a payer—with the help of the other panelists—to explain how the FDA uses gathered evidence to make decisions on approvals for PDTs.

Clinicians, pharmacists, and payers discuss how DTx and PDTs are monitored—for access, efficacy, adherence, and more.

Dr Steven Pipe delves into the economic burden associated with Hemophilia B treatment, including costs and payer considerations.

Distinctions between unbranded biologics, branded biologics, and biosimilars are explored by David Charles, MD.

Arwen Podesta, MD; Timothy Aungst, PharmD; and Scottle Whittle, MD, explain the considerations they think about before using or prescribing DTx and PDTs.

A distinguished panel provides an overview of what digital therapeutics (DTx) and prescription digital therapeutics (PDTs) are and how they’re used in behavioral health treatment.

Steven Pipe, MD, defines Hemophilia B and its standard of care.

In this second part of a two-part video series, Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency. Allen set a scope on Medicaid populations in rural settings and how they could be affected. However, there is hope through tech-based solutions and a proposed rule by CMS to prevent facility closures and preserve access to care for all affected Medicaid populations.

Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency.

Dr David Charles, MD, opens a discussion surrounding the increasing usage and unique characteristics of biologics.

MHE spoke with Matt Parker, vice president of Products at Kyruus and HealthSparq, about the recent price transparency rules that recently went into effect and how they can bring efficiency into care.

MHE spoke with Matt Parker, vice president of Products at Kyruus and HealthSparq, about the recent price transparency rules that went into effect, who they apply to and compliance improvement by insurers.

Dr Periman provides final thoughts exploring unmet clinical needs as well as forthcoming innovative opportunities in dry eye disease treatment.

Dr Laura Periman introduces current and upcoming pharmacological treatment options, including nasal varenicline, for patients with dry eye disease.

Various treatments for dry eye disease are navigated with regard to both payer and provider considerations.

Dr Periman addresses cost-related concerns associated with treating dry eye disease.

Quality-of-life concerns, including biopsychosocial impacts caused by dry eye disease, are explored by Dr Periman.

Dr Laura Periman, MD illustrates the current risk factors and prevalence regarding patients with dry eye disease.

Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.

A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.

Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.

Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.

Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.

Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.

Ryan Urgo, Managing Director, Health Policy at Avalere addressed the Biden administration’s healthcare priorities and if the Build Back Better legislation will include provisions that deal with drug prices? Urgo spoke at this year's annual Asembia Specialty Pharmacy Summit in Las Vegas on the subject, as well.

Jayne Hornung, Chief Clinical Officer, Pharmacy, MMIT addresses the difference between digital therapeutics in the pharmacy and medical benefit space, and digs into the potential causes of the slow uptake in digital therapeutics among payers during this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Doug Long, vice president of Industry Relations at IQVIA spoke on how the current inflationary trend in the economy affects healthcare spending and prices, as well as the trend of specialty drugs accounting for half of the drug spend in healthcare. Hear more of what he shared with our team at this year's Asembia Specialty Pharmacy Summit in Las Vegas.